120 related articles for article (PubMed ID: 27206322)
21. Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment.
Garcia-Souto F
An Bras Dermatol; 2021; 96(1):113-114. PubMed ID: 33272688
[No Abstract] [Full Text] [Related]
22. Subacute thyroiditis in psoriatic arthritis treated by adalimumab.
Senlis M; Ottaviani S; Gardette A; Palazzo E; Coustet B; Dieudé P
Joint Bone Spine; 2017 Dec; 84(6):745-746. PubMed ID: 27825573
[No Abstract] [Full Text] [Related]
23. Occurrence of penile intraepithelial neoplasia following adalimumab treatment for psoriatic arthritis.
Kreuter A; Meyer MF; Wieland U
Arch Dermatol; 2011 Aug; 147(8):1001-2. PubMed ID: 21844477
[No Abstract] [Full Text] [Related]
24. Case of Legionella pneumophila pneumonia (legionellosis) developed in a psoriatic arthritis patient receiving adalimumab.
Kunimoto K; Mikita N; Kanazawa N; Furukawa F
J Dermatol; 2017 Aug; 44(8):982-983. PubMed ID: 27651216
[No Abstract] [Full Text] [Related]
25. Hyperpigmentation of the face following adalimumab treatment.
Blomberg M; Zachariae CO; Grønhøj F
Acta Derm Venereol; 2009; 89(5):546-7. PubMed ID: 19734995
[No Abstract] [Full Text] [Related]
26. [Development of mesangial immunoglobulin IgA glomerulonephritis and p-ANCA positivity in a patient with psoriatic arthritis].
Nazzaro P; Battaglia R; D'Altri C; Marangi AL; Perniola M; Rodio A; De Padova F
G Ital Nefrol; 2016; 33(2):. PubMed ID: 27067220
[TBL] [Abstract][Full Text] [Related]
27. Reply to the comment of Brinster et al. "Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists".
Banse C; Vittecoq O; Lévesque H
Joint Bone Spine; 2015 Oct; 82(5):385-6. PubMed ID: 26162633
[No Abstract] [Full Text] [Related]
28. Remission of psoriatic arthritis 24 h after adalimumab therapy.
Song S; Wan L; Xia P; Chen J
Dermatol Ther; 2022 Nov; 35(11):e15807. PubMed ID: 36070202
[No Abstract] [Full Text] [Related]
29. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.
van Kuijk AW; de Groot M; Stapel SO; Dijkmans BA; Wolbink GJ; Tak PP
Ann Rheum Dis; 2010 Mar; 69(3):624-5. PubMed ID: 20223840
[No Abstract] [Full Text] [Related]
30. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
31. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
[TBL] [Abstract][Full Text] [Related]
32. Acute generalized skin eruption due to adalimumab: report of two cases.
Dalmau J; Roé E; Corella F; García-Navarro X; Peramiquel L; Alomar A
J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1105-6. PubMed ID: 17714134
[No Abstract] [Full Text] [Related]
33. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
34. Lichenoid reaction induced by adalimumab.
De Simone C; Caldarola G; D'Agostino M; Rotoli M; Capizzi R; Amerio P
J Eur Acad Dermatol Venereol; 2008 May; 22(5):626-7. PubMed ID: 18005023
[No Abstract] [Full Text] [Related]
35. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
36. Use of biologics for pustulotic arthro-osteitis in two patients with palmoplantar pustulosis.
Ohashi T; Suzuki Y; Yamamoto T
J Dermatol; 2017 Jan; 44(1):97-98. PubMed ID: 27162198
[No Abstract] [Full Text] [Related]
37. Interstitial granulomatous drug reaction to adalimumab.
Martorell-Calatayud A; Balmer N; Cardenas Cardona LF; Teague D
Am J Dermatopathol; 2010 Jun; 32(4):408-9. PubMed ID: 19940750
[No Abstract] [Full Text] [Related]
38. Psoriatic arthritis: what to do when everything fails?
Seara V; Ferro A; Marinho A
Rheumatology (Oxford); 2021 Dec; 61(1):e19-e21. PubMed ID: 34505877
[No Abstract] [Full Text] [Related]
39. Alopecia areata universalis elicited during treatment with adalimumab.
Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
[TBL] [Abstract][Full Text] [Related]
40. Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis.
Pallotta P; Cianchini G; Ruffelli M; Puddu P
Rheumatology (Oxford); 2006 Jan; 45(1):116-7. PubMed ID: 16319094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
